Dalbavancin Antibiotics

Product Name： Dalbavancin
CAS NO. 171500-79-1
English synonym:
Dalbavancin;CS-2250;Dalbavancin Ao;Dalbavancin(BI 397;DALBAVANCIN;MDL 63397;A-A-1; DALBAVANCIN AO; BI 397; MDL 63397;DALBAVANCIN(BI 397; MDL 63397);Dalbavacin;Antibotic Dalbavancin;DB/ QTH04
Molecular formula： C88H100CI2N10O28
Molecular weight: 1816.71
EINECS Number: 206-141-6
Related categories:Microbial metabolites; Dabwanxing raw materials 171500-79-1; pharmaceutical chemical materials; pharmaceutical raw materials; reference materials Chemicalbook-Chinese medicine control materials; raw materials; chemical reagents; pharmaceutical API scientific research raw materials; daily chemicals; medical raw materials; drug substances and intermediates; antibody; reference materials
The Mol file: 171500-79-1.mol
 

Structural formula:

Dabavan star nature
Melting point:> 160 C (dec.)
Density: 1.59
Storage conditions: -20 C
Solubility: alkaline solution (slightly soluble), DMSO (slightly soluble, heated), water (slightly Chemicalbook soluble)
Aciity coefficient (pK a): 2.73 ± 0.70 (Predicted)
Form: powder
Color: white to beige
Water solubility: H2O: 2 mg/mL, clear
 

Product description

Dalbavancin HCl (MDL-63397; BI-397; AA 1; VER-001; Dalvance; Xydalba (Xydalba) is a semi-synthetic lipopeptide, which is a novel and effective second-generation lipopeptide antibiotic with activity against Gram-positive pathogens. It is in the same category as vancomycin, the most widely used drug and one of the few treatments available to patients infected with methicillin-resistant Staphylococcus aureus (MRSA). Dabavacin is based on vancomycin and Teicoplanin. It has in vitro activity against a variety of Gram-positive pathogens, including MRSA and methicillin-resistant Staphylococcus epidermidis (MRSE).

In Vitro research

Dabavancin is a semi-synthetic lipopeptide that is injected parenterally to combat infections caused by drug-resistant gram-positive pathogens. Dapavancin has strong in vitro bactericidal activity against Gram-positive pathogens, including non-VANA strains of Staphylococcus aureus (MRSA), VISA and VRE. Dabavacin was developed for the treatment of complex skin and skin structure infections (csssi), primarily caused by MRSA and beta-hemolytic streptococcus, where it has shown greater efficacy compared to existing glycopeptide therapeutics.

In Vivo research

Dabavancin (15-240 mg/kg; Intraperitoneal injection; Every 36 hours or 72 hours; 14 consecutive days; Female BALB/c mice) were treated with an 80% to 100% survival rate in mice across all dose regimens [1]. Animal model: female BALB/c mice (6-8 weeks) attacked with the Ames strain of Bacillus anthracis [1] Dose: 15mg/kg, 30mg/kg, 60mg/kg, 120mg/kg, 240mg/kg, intraperitoneally injected every 36h or 72h for 14 days, the efficacy is 80-100%, as indicated by the 42-day survival rate, and 15 to 120 every 36 hours when treatment is initiated 24 hours after provocation A treatment regimen of mg/kg or 30 to 240 mg/kg every 72 hours.

Bioactivity

Dalbavancin (Zeven, BI 397, MDL 63397) is a lipoglycopeptide antibiotic with bactericidal activity against Gram-positive bacteria, such as various staphylococci.

Target spot

MIC90: 0.06 μg/mL ( Staphylococcus aureus ) and 0.25 μg/mL ( Bacillus anthracis )

Security information

MSDS information

Hot Tags: dalbavancin antibiotics, China dalbavancin antibiotics suppliers, Eribulin Mesylate, zinc sulphate topical, zinc sulfate fertilizer price, nab rapamycin, 16846-24-5, zinc sulphate medicine